JAN 0 , 2001

PATENT Attorney Docket No.: BIV-052.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)		HECEIVED
Galdes, et al.)	Art Unit: 1635	JAN 12 2001
Serial No.: 09/435,733))	Examiner: Lacourciere, K.	TECH CENTER 1600/2900
Filing Date: November 8, 1999)	·	
For: Methods and Compositions for Treating or Preventing Peripheral Neuropathies)		

Customer Number 25181

CERTIFICATE OF MAILING

I hereby certify that the foregoing document is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on Japany 272001.

Robert King

Assistant Commissioner For Patents Washington, DC 20231 BOX Sequence

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not

include new matter;

2. the content of the attached paper copy and the attached computer readable copy of

the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively,

are the same; and

3. all statements made herein of their own knowledge are true and that all statements

made on the information and belief are believed to be true; and further, that these statements

were made with the knowledge that willful false statements and the like so made are punishable

by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and

that such willful false statements may jeopardize the validity of the application or any patent

resulting therefrom.

Respectfully submitted, FOLEY, HOAG, & ELIOT

January 2, 2001

John D. Quisel

Reg. No. P-47,874

Patent Group Foley, Hoag & Eliot LLP One Post Office Square

Boston, MA 02109-2170 Tel: (617) 832-1000


Fax: (617) 832-7000



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

To Purchase Patentin Software.....703-306-2600